Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?
2014
Преузимање 🢃
Аутори
Kovač, MirjanaMiković, Zeljko
Mitić, Gorana
Đorđević, Valentina
Mandić, Vesna
Rakićević, Ljiljana
Radojković, Dragica
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The study was conducted to evaluate the effect of anticoagulant therapy in women with thrombophilia and to detect the possible differences among carriers of mutations (factor V [FV] Leiden and FIIG20210) and those with natural anticoagulant deficiency. The 4-year prospective investigation included 85 pregnant women, with a history of recurrent fetal loss (RFL). They were treated with prophylactic doses of low-molecular-weight heparin (nadroparin) starting from 6 to 8 weeks of gestation. Pregnancy outcomes were evaluated based on the thrombophilia type. Carriers of thrombophilic mutations had a live birth rate of 93%, compared to 41.6% for women with natural anticoagulant deficiencies. Significant differences between the groups were also observed for intrauterine fetal death, intrauterine growth restriction, and postpartum thrombosis. The optimal therapy for women with natural anticoagulant deficiency and RFL remains unclear and future prospective study with a large number of patients i...s required to determine the best treatment for these severe thrombophilic conditions.
Кључне речи:
pregnancy outcome / low-molecular-weight heparin / inherited thrombophiliaИзвор:
Clinical and Applied Thrombosis-Hemostasis, 2014, 20, 2, 184-189Издавач:
- Sage Publications Inc, Thousand Oaks
Финансирање / пројекти:
- Комплексне болести као модел систем за проучавање модулације фенотипа-структурна и функционална анализа молекуларних биомаркера (RS-MESTD-Basic Research (BR or ON)-173008)
DOI: 10.1177/1076029612468940
ISSN: 1076-0296
PubMed: 23262970
WoS: 000331206300012
Scopus: 2-s2.0-84893439242
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Kovač, Mirjana AU - Miković, Zeljko AU - Mitić, Gorana AU - Đorđević, Valentina AU - Mandić, Vesna AU - Rakićević, Ljiljana AU - Radojković, Dragica PY - 2014 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/783 AB - The study was conducted to evaluate the effect of anticoagulant therapy in women with thrombophilia and to detect the possible differences among carriers of mutations (factor V [FV] Leiden and FIIG20210) and those with natural anticoagulant deficiency. The 4-year prospective investigation included 85 pregnant women, with a history of recurrent fetal loss (RFL). They were treated with prophylactic doses of low-molecular-weight heparin (nadroparin) starting from 6 to 8 weeks of gestation. Pregnancy outcomes were evaluated based on the thrombophilia type. Carriers of thrombophilic mutations had a live birth rate of 93%, compared to 41.6% for women with natural anticoagulant deficiencies. Significant differences between the groups were also observed for intrauterine fetal death, intrauterine growth restriction, and postpartum thrombosis. The optimal therapy for women with natural anticoagulant deficiency and RFL remains unclear and future prospective study with a large number of patients is required to determine the best treatment for these severe thrombophilic conditions. PB - Sage Publications Inc, Thousand Oaks T2 - Clinical and Applied Thrombosis-Hemostasis T1 - Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type? EP - 189 IS - 2 SP - 184 VL - 20 DO - 10.1177/1076029612468940 ER -
@article{ author = "Kovač, Mirjana and Miković, Zeljko and Mitić, Gorana and Đorđević, Valentina and Mandić, Vesna and Rakićević, Ljiljana and Radojković, Dragica", year = "2014", abstract = "The study was conducted to evaluate the effect of anticoagulant therapy in women with thrombophilia and to detect the possible differences among carriers of mutations (factor V [FV] Leiden and FIIG20210) and those with natural anticoagulant deficiency. The 4-year prospective investigation included 85 pregnant women, with a history of recurrent fetal loss (RFL). They were treated with prophylactic doses of low-molecular-weight heparin (nadroparin) starting from 6 to 8 weeks of gestation. Pregnancy outcomes were evaluated based on the thrombophilia type. Carriers of thrombophilic mutations had a live birth rate of 93%, compared to 41.6% for women with natural anticoagulant deficiencies. Significant differences between the groups were also observed for intrauterine fetal death, intrauterine growth restriction, and postpartum thrombosis. The optimal therapy for women with natural anticoagulant deficiency and RFL remains unclear and future prospective study with a large number of patients is required to determine the best treatment for these severe thrombophilic conditions.", publisher = "Sage Publications Inc, Thousand Oaks", journal = "Clinical and Applied Thrombosis-Hemostasis", title = "Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?", pages = "189-184", number = "2", volume = "20", doi = "10.1177/1076029612468940" }
Kovač, M., Miković, Z., Mitić, G., Đorđević, V., Mandić, V., Rakićević, L.,& Radojković, D.. (2014). Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?. in Clinical and Applied Thrombosis-Hemostasis Sage Publications Inc, Thousand Oaks., 20(2), 184-189. https://doi.org/10.1177/1076029612468940
Kovač M, Miković Z, Mitić G, Đorđević V, Mandić V, Rakićević L, Radojković D. Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?. in Clinical and Applied Thrombosis-Hemostasis. 2014;20(2):184-189. doi:10.1177/1076029612468940 .
Kovač, Mirjana, Miković, Zeljko, Mitić, Gorana, Đorđević, Valentina, Mandić, Vesna, Rakićević, Ljiljana, Radojković, Dragica, "Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?" in Clinical and Applied Thrombosis-Hemostasis, 20, no. 2 (2014):184-189, https://doi.org/10.1177/1076029612468940 . .